TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...
The resulting paper, "HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease," appears in the American Journal of Gastroenterology.
TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the ...
Tofacitinib and TNF inhibitors demonstrated similar efficacy for managing RA at 12 months, with minor differences noted across tofacitinib treatment lines.
TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to ...